Filing Details

Accession Number:
0001062993-23-018019
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-14 16:13:21
Reporting Period:
2023-09-12
Accepted Time:
2023-09-14 16:13:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621443 Zynerba Pharmaceuticals Inc. ZYNE Pharmaceutical Preparations (2834) 260389433
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1988882 T Kenneth Jones C/O Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon PA 19333
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-09-12 9,000 $0.00 88,025 No 4 A Direct
Common Stock Disposition 2023-09-13 2,505 $1.33 85,520 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 9,000 performance-based restricted stock awards granted in a prior year.
  2. This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.